Phase III data shows benefits with AMG 145 in HoFH - Amgen

Phase III data from the TESLA study showed that adding AMG 145 (evolocumab) 420 mg subcutaneous monthly, from Amgen, to a stable dose of statin therapy and other lipid-lowering medications significantly reduced LDL-C by 31 percent (p<0.001) from baseline at week 12 compared to placebo in patients with homozygous familial hypercholesterolemia hofh. in the phase iii tesla study in 49 hofh patients the most common adverse events in the evolocumab group were upper respiratory tract infection three patients on evolocumab one patient on placebo influenza three patients on evolocumab 0 patients on placebo gastroenteritis two patients on evolocumab 0 patients on placebo and nasopharyngitis two patients on evolocumab 0 patients on placebo.>

Results from the TESLA study, along with preliminary findings from the Phase II/III TAUSSIG study in patients with severe familial hypercholesterolemia (FH), were presented at the 82nd Congress of the European Atherosclerosis Society (EAS 2014).